Matthew Scott Harris - 28 Feb 2022 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Medical Officer
Signature
/s/ Kent Tapper, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
28 Feb 2022
Net transactions value
-$167,961
Form type
4
Filing time
02 Mar 2022, 18:00:41 UTC
Previous filing
03 Feb 2022
Next filing
03 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Options Exercise $57,639 +30,000 +260% $1.92 41,545 28 Feb 2022 Direct
transaction ALT Common Stock, par value $0.0001 Sale $225,600 -30,000 -72% $7.52 11,545 28 Feb 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Options Exercise $0 -30,000 -49% $0.000000 31,400 28 Feb 2022 Common Stock, par value $0.0001 30,000 $1.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.70, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 Twenty-five percent of the shares underlying the option became vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date.